(Q53060957)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Baxter H Kachingwe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Y T Hsu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

C Y Hsu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Y S Uang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

L H Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

24 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

354-360

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661226%20AND%20SRC:MED&resulttype=core&format=json

Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Obesity and prostate cancer: a role for adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Function of PPARgamma and its ligands in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Cohort study of pioglitazone and cancer incidence in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Association between pioglitazone and urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Type 2 diabetes in Asians: prevalence, risk factors, and effectiveness of behavioral intervention at individual and population levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151

Does diabetes therapy influence the risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12151